New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson &Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more difficult to treat.1,2 These results are among the 34 scientific abstracts Janssen is presenting from the Company’s rheumatology portfolio at the EULAR E-Congress, many of which feature TREMFYA, the only selective IL-23 inhibitor therapy approved in the U.S. to treat both adults with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy, as well as adults with active PsA.3PsA is a chronic, progressive, immune-mediated disease characterized by pain, stiffness, and swelling in and around both peripheral and axial joints as well as itch and discomfort from skin lesions.4 People living with PsA can also suffer from sleep disorders, fatigue, stress, and depression.5 Janssen data shared at EULAR show the severity of skin and joint symptoms of active PsA was significantly associated with a higher loss of work produc...
Conclusions For the two scenarios tested, more relevant CAPAs were identified with the new tool than with usual tools. Further research is needed to assess the effectiveness of the new tool for other types of adverse events and its impact on patient safety.
This study aims to address the patient safety performance status at hospitals implementing the PPSCF. Methods A nationwide questionnaire survey targeting 2674 hospitals with the PPSCF was performed in 2010 to 2011. The 627 participant hospitals were divided into the following three groups: 178 hospitals implementing PPSCF 1 with 400 beds or more (group A), 286 hospitals implementing PPSCF 1 with 399 beds or fewer (group B), and 163 hospitals implementing PPSCF 2 (group C). Results The mean numbers (standard errors) of patient safety managers were 1.45 (0.07) in group A, 1.12 (0.04) in group B, and 0.37 (0.12) in group C (P
Conclusions Analysis of ASC and HOR claims demonstrates significant differences and several common sources of liability. These include improving strategies for thorough screening, preoperative assessment and risk stratifying of patients, incorporating routine dental and airway assessment and documentation, diagnosing and treating perioperative pain adequately, and improving the efficacy of communication between patients and care providers.
Conclusions We have developed scales measuring exposure and responses to disruptive behavior. They generate valid and reliable scores when surveying operating room clinicians, and they overcome the limitations of previous tools. These survey scales are freely available.
Conclusion These results illustrate that misidentification errors are still common in France. This work contributes to enhancing interest in IRS data analysis to define or refine patient safety improvement strategies related to misidentification errors in healthcare institutions.
Objective First, the aim of the study was to assess the prevalence, characteristics, and severity of unintended medication discrepancies (UMDs) and medication errors (MEs) at admission and discharge of hospitalization. Second, the aim of the study was to identify clinical and hospitalization factors associated with risk of UMDs as well as characteristics of the medication reconciliation process associated with UMDs detection. Methods This prospective observational study included all adult patients admitted from 2013 to 2015 in the Endocrinology-Diabetology-Nutrition Department of Montpellier Hospital, France. Cl...
I’ve been interviewing for jobs recently and am realizing how much of private practice pain is just a money making scheme. Comments like “schedule the procedure and medication refills on the same day so they come to get their procedure,” and “3-4 shots a year and a couple urines is not bad revenue” are so common. Tack on sketchy urine labs, churning out patients with scribes, getting paid $$$ by industry and the situation seems even more bleak. my question is - is this unique to pain? On... Read more
Hello all, I I'm finishing my fellowship and was recommended for a job at a clinic. I had a phone interview with them today which went very well. They asked me to come see the facility in person at the end of the interview and had mentioned that they would like me to sign an NDA before seeing the clinic at the end of the interview. I'm very new to this and I'm not sure if this is the norm. My question is, I'm not sure what can be confidential/proprietary in a clinic setting and if I sign... Read more
Conclusions Adults with cerebral palsy or spina bifida have a significantly higher prevalence of common psychological, cardiometabolic, and musculoskeletal morbidity and multimorbidity, as compared with adults without cerebral palsy or spina bifida. Efforts are needed to facilitate the development of improved clinical screening algorithms and early interventions to reduce risk of disease onset/progression in these higher risk populations. To Claim CME Credits Complete the self-assessment activity and evaluation online at http://www.physiatry.org/JournalCME CME Objectives Upon completion of this article, t...
Objective The aim of the study was to assess centrally induced pain processing with pressure pain thresholds bilaterally and remotely in active volleyball and basketball athletes with mild patellar tendinopathy compared with asymptomatic control athletes. Secondary objective was to explore the role of exercise-induced analgesia during a training session in athletes with patellar tendinopathy. Design In this exploratory study, pressure pain thresholds of 21 patellar tendinopathy athletes and 16 age- and sex-matched asymptomatic team members were measured by a blinded assessor bilaterally on the patellar tendon an...
More News: Allergy & Immunology | Ankylosing Spondylitis | Anxiety | Arthritis | Babies | Babies Heart Conditions | Back Pain | Brain | Breastfed | Bronchitis | Canada Health | Cancer & Oncology | Cardiology | Cardiovascular | Chronic Pain | Clinical Trials | Cold Sores | Complementary Medicine | Depression | Dermatology | Disability | Eating Disorders & Weight Management | Economics | Emergency Medicine | Enbrel | Environmental Health | Food and Drug Administration (FDA) | France Health | Gastroenteritis | Gastroenterology | Genetics | Headache | Health Management | Heart | Herbs | Herpes | Hospitals | Humira | Hypertension | Infectious Diseases | Inflammatory Bowel Disease | Itchiness | Japan Health | Learning | Legislation | Marketing | Migraine | Milk | Neurology | Neuroscience | Obesity | Pain | Pain Management | Pharmaceuticals | Politics | Pregnancy | Profits and Losses | Psoriasis | Psoriatic Arthritis | Psychology | Pulmonary Hypertension | Radiography | Remicade | Respiratory Medicine | Rheumatology | Science | Skin | Sleep Disorders | Sleep Medicine | Stelara | Study | Tuberculosis | Universities & Medical Training | Vaccines | Vitamins | Websites